Skip to content
10-K

Annual Report

ArriVent BioPharma, Inc. AVBP

0001558370-25-001999

← back to feed
Filed
Mar 3, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 28, 2025 34.02M sh
Shares Diluted FY 2024 · Dec 31, 2023 2.14M sh
Operating Cash Flow FY 2024 · Dec 31, 2023 −$55.84M
Cash And Equivalents FY 2024 · Dec 31, 2023 $150.39M
Current Liabilities FY 2024 · Dec 31, 2023 $11.62M
Total Liabilities FY 2024 · Dec 31, 2023 $11.8M
Current Assets FY 2024 · Dec 31, 2023 $159.97M
Total Assets FY 2024 · Dec 31, 2023 $163.1M
Eps Diluted FY 2024 · Dec 31, 2023 −$32.38
Eps Basic FY 2024 · Dec 31, 2023 −$32.38
Sga Expense FY 2024 · Dec 31, 2023 $9.71M
Rd Expense FY 2024 · Dec 31, 2023 $64.88M
Net Income FY 2024 · Dec 31, 2023 −$69.33M
Operating Income FY 2024 · Dec 31, 2023 −$74.59M
Stockholders Equity FY 2024 · Dec 31, 2022 −$85.11M